美國參議院辯論如何降低高昂藥價
U.S. Senate Debates How to Lower High Drug Prices
多年來，美國參議院一直在積極辯論如何降低高昂的處方藥價格，這是一個深遠影響數百萬個家庭的問題。
For years, the U.S.
一個重要的里程碑是2022年的《降低通膨法案》(Inflation Reduction Act, IRA)，該法案允許聯邦醫療保險與特定藥價進行談判，並將胰島素的費用限制在每月35美元。
Senate has been actively debating how to lower high prescription drug prices, an issue that deeply affects millions of families.
立法者目前正在審查藥房福利管理機構——即供應鏈中的中間商——他們被指控偏好昂貴藥物以增加自身的利潤。
While the IRA was a significant step, the focus has now shifted toward more targeted reforms.
另一個熱門話題是「專利叢林」(patent thickets，ㄓㄨㄢㄌㄧˋㄘㄨㄥˊㄌㄧㄣˊ)，即公司利用過多的專利來阻止更便宜的學名藥進入市場。
Lawmakers are currently scrutinizing Pharmacy Benefit Managers (PBMs)—the middlemen in the supply chain—who are accused of favoring expensive drugs to boost their own profits.
隨著參議院委員會持續舉行聽證會，目標依然明確：在不阻礙未來藥物研發的前提下，讓民眾負擔得起救命藥物。
Despite these political differences, there is strong bipartisan agreement on one thing: the current system lacks transparency.
